Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01745588 · OUTCOME

Median Overall Survival

Autologous Stem Cell Transplant With Pomalidomide (CC-4047®) Maintenance Versus Continuous Clarithromycin/ Pomalidomide / Dexamethasone Salvage Therapy in Relapsed or Refractory Multiple Myeloma · Source last updated 2026-09-25

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
Full Range
Time frame
up to 118 months

What was measured

Overall survival rate

Groups in this outcome

Clarithromycin + Pomalidomide + Dexamethasone + Stem Cell

All patients will receive 4 cycles of clarithromycin 500mg twice daily on days 1-28, pomalidomide 4 mg daily on days 1 through 21 and dexamethasone orally at a dose of 40 mg daily on days 1, 8, 15, and 22 of each 28-day cycle. Patients randomized to auto-SCT will proceed within 28 days after completion of the 4th cycle of ClaPD to receive melphalan 140mg/m2 or 200mg/m2 (as per institutional guidelines) followed by hematopoietic cell infusion. Pomalidomide stem cell Clarithromycin

Clarithromycin + Pomalidomide + Dexamethasone Alone

All patients will receive 4 cycles of clarithromycin 500mg twice daily on days 1-28 pomalidomide 4 mg daily on days 1 through 21 and dexamethasone orally at a dose of 40 mg daily on days 1, 8, 15, and 22 of each 28 day cycle. Patients assigned to ClaPD alone will receive 5 additional cycles of ClaPD. Pomalidomide Dexamethasone Clarithromycin

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Clarithromycin + Pomalidomide + Dexamethasone + Stem Cell12
Clarithromycin + Pomalidomide + Dexamethasone Alone11

Reported measurements

Source class 1
Values in months · Interval/dispersion: Full Range
GroupValueSpreadLowerUpperComment
Clarithromycin + Pomalidomide + Dexamethasone + Stem Cell35Not reported10118Not reported
Clarithromycin + Pomalidomide + Dexamethasone Alone47Not reported388Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        10
        upper Limit
        118
        value
        35
      2. group Id
        OG001
        lower Limit
        3
        upper Limit
        88
        value
        47
denoms
  1. counts
    1. group Id
      OG000
      value
      12
    2. group Id
      OG001
      value
      11
    units
    Participants
description
Overall survival rate
dispersion Type
Full Range
groups
  1. description
    All patients will receive 4 cycles of clarithromycin 500mg twice daily on days 1-28, pomalidomide 4 mg daily on days 1 through 21 and dexamethasone orally at a dose of 40 mg daily on days 1, 8, 15, and 22 of each 28-day cycle. Patients randomized to auto-SCT will proceed within 28 days after completion of the 4th cycle of ClaPD to receive melphalan 140mg/m2 or 200mg/m2 (as per institutional guidelines) followed by hematopoietic cell infusion. Pomalidomide stem cell Clarithromycin
    id
    OG000
    title
    Clarithromycin + Pomalidomide + Dexamethasone + Stem Cell
  2. description
    All patients will receive 4 cycles of clarithromycin 500mg twice daily on days 1-28 pomalidomide 4 mg daily on days 1 through 21 and dexamethasone orally at a dose of 40 mg daily on days 1, 8, 15, and 22 of each 28 day cycle. Patients assigned to ClaPD alone will receive 5 additional cycles of ClaPD. Pomalidomide Dexamethasone Clarithromycin
    id
    OG001
    title
    Clarithromycin + Pomalidomide + Dexamethasone Alone
param Type
MEDIAN
reporting Status
POSTED
time Frame
up to 118 months
title
Median Overall Survival
type
SECONDARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-d643ffaf417bcef6d45eb5e0

Preserved source evidence · Not medical advice